Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1

References

• Santarpia M, Rolfo C, Peters GJ, et al. On the pharmacogenetics of non-small cell lung cancer treatment. Expert Opin Drug Metab Toxicol. 2016;12:307–317.
   PubMed Web of Science ®Google Scholar
• Lee JW, Aminkeng F, Bhavsar AP, et al. The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet. 2014;86:21–28.
   PubMed Web of Science ®Google Scholar
• Allingham-Hawkins D, Lea A, Levine S. ERCC1 expression analysis to guide therapy in non-small cell lung cancer. PLoS Curr. 2010;2:RRN1202.
   PubMedGoogle Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Fennell DA, Summers Y, Cadranel J, et al. Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 2016;44:42–50.
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847–857.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98.
   PubMed Web of Science ®Google Scholar
• Dietrich MF, Gerber DE. Chemotherapy for advanced non-small cell lung cancer. Cancer Treat Res. 2016;170:119–149.
   PubMedGoogle Scholar
• McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009;8:10–16.
   PubMed Web of Science ®Google Scholar
• Rosenberg B, Van Camp L, Trosko JE, et al. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222:385–386.
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Int Med. 1981;95:414–420.
   PubMed Web of Science ®Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573–584.
   PubMed Web of Science ®Google Scholar
• Roco A, Cayún J, Contreras S, et al. Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy? Front Genet. 2014;5:391.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012 Apr 12;31(15):1869–1883.
   PubMed Web of Science ®Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311:899–909.
   PubMed Web of Science ®Google Scholar
• Pignon J-P, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–3559.
   PubMed Web of Science ®Google Scholar
• Yin J-Y, Li X, Zhou H-H, et al. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine. Pharmacogenomics. 2016;17:1365–1378.
   PubMed Web of Science ®Google Scholar
• Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 2011;71:3–10.
   PubMed Web of Science ®Google Scholar
• Kelland LR. New platinum antitumor complexes. Crit Rev Oncol Hematol. 1993;15:191–219.
   PubMed Web of Science ®Google Scholar
• Olszewski U, Hamilton G. A better platinum-based anticancer drug yet to come? Anticancer Agents Med Chem. 2010;10:293–301.
   PubMed Web of Science ®Google Scholar
• Spivak G. Nucleotide excision repair in humans. DNA Repair (Amst). 2015;36:13–18.
   PubMed Web of Science ®Google Scholar
• Sakthivel KM, Hariharan S. Regulatory players of DNA damage repair mechanisms: role in cancer chemoresistance. Biomed Pharmacother. 2017;93:1238–1245.
   PubMed Web of Science ®Google Scholar
• Camps C, Sirera R, Iranzo V, et al. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer. 2007;8:369–375.
   PubMed Web of Science ®Google Scholar
• Malottki K, Popat S, Deeks JJ, et al. Problems of variable biomarker evaluation in stratified medicine research – a case study of ERCC1 in non-small-cell lung cancer. Lung Cancer. 2016;92:1–7.
   PubMed Web of Science ®Google Scholar
• Friboulet L, Olaussen KA, Pignon J-P, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368:1101–1110.
   PubMed Web of Science ®Google Scholar
• Olaussen KA, Postel-Vinay S. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Ann Oncol. 2016;27:2004–2016.
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529–537.
   PubMed Web of Science ®Google Scholar
• Pérez-Ramírez C, Cañadas-Garre M, Molina MÁ, et al. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer. Mutat Res. 2017;771:32–58.
   PubMed Web of Science ®Google Scholar
• Chen J, Emara N, Solomides C, et al. Resistance to platinum-based chemotherapy in lung cancer cell lines. Cancer Chemother Pharmacol. 2010 Nov;66(6):1103–1111.
   PubMed Web of Science ®Google Scholar
• Rose MC, Kostyanovskaya E, Huang RS. Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer. Genom Proteom Bioinform. 2014;12:198–209.
   PubMedGoogle Scholar
• Chen X, Sun H, Ren S, et al. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clin Transl Oncol. 2012;14:207–213.
   PubMed Web of Science ®Google Scholar
• Xiang T, Kang X, Gong Z, et al. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies. Cancer Chemother Pharmacol. 2017;79:791–800.
   PubMed Web of Science ®Google Scholar
• Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004;10:4939–4943.
   PubMed Web of Science ®Google Scholar
• Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer. 2010;67:101–107.
   PubMed Web of Science ®Google Scholar
• Huang S-J, Wang Y-F, Jin Z-Y, et al. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer. Tumour Biol. 2014;35:4023–4029.
   PubMedGoogle Scholar
• Zhao X, Zhang Z, Yuan Y, et al. Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients. Tumour Biol. 2014;35:8335–8341.
   PubMedGoogle Scholar
• Gao H, Ge RC, Liu HY, et al. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer. Genet Mol Res. 2014;13:8997–9004.
   PubMed Web of Science ®Google Scholar
• Li F, Sun X, Sun N, et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol. 2010;33:489–494.
   PubMed Web of Science ®Google Scholar
• Okuda K, Sasaki H, Hikosaka Y, et al. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res. 2011;168:206–212.
   PubMed Web of Science ®Google Scholar
• Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10:118–123.
   PubMed Web of Science ®Google Scholar
• Shi Z-H, Shi G-Y, Liu L-G. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8:3132–3137.
   PubMed Web of Science ®Google Scholar
• Park S-Y, Hong Y-C, Kim J-H, et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol. 2006;23:489–498.
   PubMed Web of Science ®Google Scholar
• Lv H, Han T, Shi X, et al. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer. Med Oncol. 2014;31:86.
   PubMed Web of Science ®Google Scholar
• Cheng J, Ha M, Wang Y, et al. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2012;138:231–238.
   PubMed Web of Science ®Google Scholar
• Joerger M, Burgers SA, Baas P, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 2012;118:2466–2475.
   PubMed Web of Science ®Google Scholar
• Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer. 2007;56:281–288.
   PubMed Web of Science ®Google Scholar
• Ryu J-S, Hong Y-C, Han H-S, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer. 2004;44:311–316.
   PubMed Web of Science ®Google Scholar
• Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15:1194–1203.
   PubMed Web of Science ®Google Scholar
• Ren S, Zhou S, Wu F, et al. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer. 2012;75:102–109.
   PubMed Web of Science ®Google Scholar
• Geredeli C, Artac M, Yildirim S, et al. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer. Tumour Biol. 2015;36:4279–4285.
   PubMedGoogle Scholar
• Mlak R, Krawczyk P, Ramlau R, et al. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Oncol Rep. 2013;30:2385–2398.
   PubMed Web of Science ®Google Scholar
• de las Peñas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol. 2006;17:668–675.
   PubMed Web of Science ®Google Scholar
• Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14:1797–1803.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xian L. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol. 2014;35:2905–2921.
   PubMedGoogle Scholar
• Yu S-N, Liu G-F, Li X-F, et al. Evaluation of prediction of polymorphisms of DNA repair genes on the efficacy of platinum-based chemotherapy in patients with non-small cell lung cancer: a network meta-analysis. J Cell Biochem. 2017;118:4782–4791.
   PubMed Web of Science ®Google Scholar
• Xu T-P, Shen H, Liu L-X, et al. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene. 2013;526:265–274.
   PubMed Web of Science ®Google Scholar
• Han Y, Liu J, Sun M, et al. A significant statistical advancement on the predictive values of ERCC1 polymorphisms for clinical outcomes of platinum-based chemotherapy in non-small cell lung cancer: an updated meta-analysis. Dis Markers. 2016;2016:1–13.
   Google Scholar
• Huang D, Zhou Y. Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: a meta-analysis based on 44 studies. Biomed Rep. 2014;2:452–462.
   PubMedGoogle Scholar
• Yu D, Shi J, Sun T, et al. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumour Biol. 2012;33:877–884.
   PubMedGoogle Scholar
• Yin M, Yan J, Voutsina A, et al. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer. 2011;72:370–377.
   PubMed Web of Science ®Google Scholar
• Patel JN. Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives. Pharmgenom Pers Med. 2016;9:65–77.
   PubMed Web of Science ®Google Scholar
• Macerelli M, Ganzinelli M, Gouedard C, et al. Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer? Cancer Treat Rev. 2016;48:8–19.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Huang B-Y, Yin J-Y. Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems. Med Oncol. 2017;34:48.
   PubMed Web of Science ®Google Scholar
• Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic. Nature. 2013;501:355–364.
   PubMed Web of Science ®Google Scholar
• Hartford CM, Eileen Dolan M. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics. 2007;8:1159–1168.
   PubMed Web of Science ®Google Scholar
• Bepler G, Williams C, Schell MJ, et al. Randomized international phase III trial of ERCC1 and RRM1 expression–based chemotherapy versus gemcitabine/carboplatin in advanced non–small-cell lung cancer. J Clin Oncol. 2013;31:2404–2412.
   PubMed Web of Science ®Google Scholar
• Heo SJ, Jung I, Lee C-K, et al. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2016;77:539–548.
   PubMed Web of Science ®Google Scholar
• Sullivan I, Salazar J, Majem M, et al. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett. 2014;353:160–166.
   PubMed Web of Science ®Google Scholar
• Wu X, Lu C, Ye Y, et al. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genom. 2008;18(11):955–965.
   PubMed Web of Science ®Google Scholar
• Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol. 2009;5:745–755.
   PubMed Web of Science ®Google Scholar
• Li Q, Gardner K, Zhang L, et al. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem. 1998;273:23419–23425.
   PubMed Web of Science ®Google Scholar
• Lefkofsky HB, Veloso A, Ljungman M. Transcriptional and post-transcriptional regulation of nucleotide excision repair genes in human cells. Mutat Res. 2015;776:9–15.
   PubMed Web of Science ®Google Scholar
• Mogi A, Kuwano H. TP53 mutations in non-small cell lung cancer. J Biomed Biotechnol. 2011;2011:583929.
   PubMedGoogle Scholar
• Christmann M, Kaina B. Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucl Acid Res. 2013;41:8403–8420.
   PubMed Web of Science ®Google Scholar
• Moufarij MA, Phillips DR, Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol. 2003 Apr;63(4):862–869.
   PubMed Web of Science ®Google Scholar
• Poruchynsky MS, Komlodi-Pasztor E, Trostel S, et al. Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins. Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1571–1576.
   PubMed Web of Science ®Google Scholar
• O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547–560.
   PubMed Web of Science ®Google Scholar
• Gonzalez VM, Fuertes MA, Alonso C, et al. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol. 2001;59:657–663.
   PubMed Web of Science ®Google Scholar
• Mandic A, Hansson J, Linder S, et al. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem. 2003;278:9100–9106.
   PubMed Web of Science ®Google Scholar
• Berndtsson M, Hägg M, Panaretakis T, et al. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer. 2007;120:175–180.
   PubMed Web of Science ®Google Scholar
• Bramson J, Panasci LC. Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents. Cancer Res. 1993;53:3237–3240.
   PubMed Web of Science ®Google Scholar
• Niedernhofer LJ, Odijk H, Budzowska M, et al. The structure-specific endonuclease ERCC1-XPF is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol. 2004;24:5776–5787.
   PubMed Web of Science ®Google Scholar
• Tiseo M, Bordi P, Bortesi B, et al.; Bio-FAST Trial Group. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer. 2013;108:1695–1703.
   PubMed Web of Science ®Google Scholar
• Tao H, Zhang Y, Li Q, et al. Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review. J Cancer Res Clin Oncol. 2017;143:2245–2256.
   PubMed Web of Science ®Google Scholar